Segment, Customer and Geographical Reporting (Tables)

9 Months Ended

Jun. 30, 2019

Segment, Customer and Geographical Reporting

Schedule of Segment reporting information

The Company’s segment information for the three months ended June 30, 2019 and 2018 is summarized below:

Results of Operations for the Three Months Ended June 30,

2019

				Innovation and
	Optics			Development*			Biomedical		Total
Revenue	$	5,899,000		$	5,191,000		$	—	$	11,090,000
Gross profit		2,112,000			1,994,000			—		4,106,000
GM %		36	%		38	%		—		37	%
Operating expenses		2,237,000			1,992,000			23,000		4,252,000
Operating income (loss)		(125,000)			2,000			(23,000)		(146,000)
Depreciation and amortization		297,000			63,000			3,000		363,000
Capital expenditures		90,000			29,000			—		119,000
Intangibles, net		334,000			136,000			195,000		665,000
Goodwill		925,000			4,939,000			—		5,864,000
Total assets	$	21,084,000		$	10,805,000		$	201,000	$	32,090,000

Results of Operations for the Three Months Ended June 30,

2018

				Innovation and
	Optics			Development*			Biomedical		Total
Revenue	$	6,159,000		$	4,383,000		$	—	$	10,542,000
Gross profit		2,299,000			1,876,000			—		4,175,000
GM %		37	%		43	%		—		40	%
Operating expenses		1,721,000			1,760,000			84,000		3,565,000
Operating income (loss)		578,000			116,000			(84,000)		610,000
Depreciation and amortization		261,000			53,000			3,000		317,000
Capital expenditures		707,000			76,000			20,000		803,000
Intangibles, net		408,000			171,000			380,000		959,000
Goodwill		968,000			4,939,000			—		5,907,000
Total assets	$	21,117,000		$	8,018,000		$	507,000	$	29,642,000

*Formerly Contract Research

The Company’s segment information for the nine months ended June 30, 2019 and 2018 is summarized below:

Results of Operations for the Nine Months Ended June 30,

2019

				Innovation and
	Optics			Development*			Biomedical		Total
Revenue	$	17,846,000		$	14,804,000		$	—	$	32,650,000
Gross profit		6,121,000			6,035,000			—		12,156,000
GM %		34	%		41	%		—		37	%
Operating expenses		5,993,000			6,012,000			98,000		12,103,000
Operating income (loss)		128,000			23,000			(98,000)		53,000
Depreciation and amortization		863,000			183,000			10,000		1,056,000
Capital expenditures		586,000			93,000			—		679,000
Intangibles, net		334,000			136,000			195,000		665,000
Goodwill		925,000			4,939,000			—		5,864,000
Total assets	$	21,084,000		$	10,805,000		$	201,000	$	32,090,000

Results of Operations for the Nine Months Ended June 30,

2018

				Innovation and
	Optics			Development*			Biomedical		Total
Revenue	$	17,011,000		$	12,974,000		$	—	$	29,985,000
Gross profit		6,038,000			5,621,000			—		11,659,000
GM %		35	%		43	%		—		39	%
Operating expenses		5,154,000			5,297,000			724,000		11,175,000
Operating income (loss)		884,000			324,000			(724,000)		484,000
Depreciation and amortization		738,000			179,000			10,000		927,000
Capital expenditures		1,635,000			153,000			65,000		1,853,000
Intangibles, net		408,000			171,000			380,000		959,000
Goodwill		968,000			4,939,000			—		5,907,000
Total assets	$	21,117,000		$	8,018,000		$	507,000	$	29,642,000

*Formerly Contract Research

Schedule Of Segment revenue

Revenue by geographic location in total and as a percentage of total revenue, for the three months ended June 30, 2019 and 2018 are as follows:

	Three Months Ended				Three Months Ended
	June 30, 2019				June 30, 2018
Geographic Location		Revenue	% of Total			Revenue	% of Total
United States	$	8,669,000	78	%	$	7,512,000	71	%
Asia		667,000	6	%		877,000	9	%
Europe		1,468,000	13	%		2,029,000	19	%
Other		286,000	3	%		124,000	1	%
	$	11,090,000	100	%	$	10,542,000	100	%

Revenue by geographic location in total and as a percentage of total revenue, for the nine months ended June 30, 2019 and 2018 are as follows:

	Nine Months Ended				Nine Months Ended
	June 30, 2019				June 30, 2018
Geographic Location		Revenue	% of Total			Revenue	% of Total
United States	$	24,901,000	76	%	$	22,993,000	76	%
Asia		2,462,000	8	%		877,000	3	%
Europe		4,705,000	14	%		4,662,000	16	%
Other		582,000	2	%		1,453,000	5	%
	$	32,650,000	100	%	$	29,985,000	100	%